KR101923746B1 - 후생적 효소의 조절자로서의 치환된 퓨린 및 7-데아자퓨린 화합물 - Google Patents

후생적 효소의 조절자로서의 치환된 퓨린 및 7-데아자퓨린 화합물 Download PDF

Info

Publication number
KR101923746B1
KR101923746B1 KR1020137017337A KR20137017337A KR101923746B1 KR 101923746 B1 KR101923746 B1 KR 101923746B1 KR 1020137017337 A KR1020137017337 A KR 1020137017337A KR 20137017337 A KR20137017337 A KR 20137017337A KR 101923746 B1 KR101923746 B1 KR 101923746B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
halo
cancer
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137017337A
Other languages
English (en)
Korean (ko)
Other versions
KR20130125379A (ko
Inventor
에드워드 제임스 올하바
리차드 체스워쓰
케빈 웨인 쿤츠
빅토리아 마리 리츤
로이 맥파레인 폴록
스코트 리차드 데이글
Original Assignee
에피자임, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에피자임, 인코포레이티드 filed Critical 에피자임, 인코포레이티드
Publication of KR20130125379A publication Critical patent/KR20130125379A/ko
Application granted granted Critical
Publication of KR101923746B1 publication Critical patent/KR101923746B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1020137017337A 2010-12-03 2011-12-02 후생적 효소의 조절자로서의 치환된 퓨린 및 7-데아자퓨린 화합물 Expired - Fee Related KR101923746B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41966110P 2010-12-03 2010-12-03
US61/419,661 2010-12-03
PCT/US2011/063044 WO2012075381A1 (en) 2010-12-03 2011-12-02 Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes

Publications (2)

Publication Number Publication Date
KR20130125379A KR20130125379A (ko) 2013-11-18
KR101923746B1 true KR101923746B1 (ko) 2018-11-29

Family

ID=45444712

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137017337A Expired - Fee Related KR101923746B1 (ko) 2010-12-03 2011-12-02 후생적 효소의 조절자로서의 치환된 퓨린 및 7-데아자퓨린 화합물

Country Status (18)

Country Link
US (5) US8580762B2 (OSRAM)
EP (1) EP2646444B1 (OSRAM)
JP (1) JP5931905B2 (OSRAM)
KR (1) KR101923746B1 (OSRAM)
CN (1) CN103391939B (OSRAM)
AR (1) AR084408A1 (OSRAM)
AU (1) AU2011336415B2 (OSRAM)
BR (1) BR112013013659B8 (OSRAM)
CA (1) CA2819648C (OSRAM)
DK (1) DK2646444T3 (OSRAM)
ES (1) ES2577027T3 (OSRAM)
HR (1) HRP20160655T1 (OSRAM)
IL (1) IL226651A (OSRAM)
MX (1) MX2013006251A (OSRAM)
RU (1) RU2606514C2 (OSRAM)
SI (1) SI2646444T1 (OSRAM)
TW (1) TWI537271B (OSRAM)
WO (1) WO2012075381A1 (OSRAM)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130124959A (ko) 2010-12-03 2013-11-15 에피자임, 인코포레이티드 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법
EP2646441B1 (en) 2010-12-03 2015-12-02 Epizyme, Inc. Carbocycle-substituted purine and 7-deazapurine compounds
SI2646444T1 (sl) * 2010-12-03 2016-09-30 Epizyme, Inc. Substituirane spojine purina in 7-deazapurina kot modulatorji epigenetskih encimov
WO2012082436A2 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
US9670463B2 (en) 2011-10-14 2017-06-06 Children's Medical Center Corporation Inhibition and enhancement of reprogramming by chromatin modifying enzymes
EP2794627B1 (en) 2011-12-22 2018-09-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20150284422A1 (en) 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
EP2892536B1 (en) 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
JP2016510316A (ja) * 2012-12-21 2016-04-07 エピザイム，インコーポレイティド 白血病の治療に使用するためのｄｏｔ１ｌ阻害剤
SI3290421T1 (sl) 2013-02-22 2019-03-29 Pfizer Inc. Kombinacija derivatov pirolo (2,3-D)pirimidina z enim ali več dodatnimi sredstvi za zaviranje z janusom povezane kinaze (JAK)
WO2014178954A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
US20160031839A1 (en) 2013-03-14 2016-02-04 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153001A1 (en) * 2013-03-14 2014-09-25 Epizyme, Inc. Combination therapy for treating cancer
WO2014152261A1 (en) * 2013-03-14 2014-09-25 Epizyme, Inc. Substituted 7-deazapurine compounds
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9045455B2 (en) 2013-03-14 2015-06-02 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9446064B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
SI2970132T1 (sl) 2013-03-14 2021-02-26 Epizyme, Inc. Inhibitorji argininmetiltransferaze in njihove uporabe
US8952026B2 (en) 2013-03-14 2015-02-10 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9765035B2 (en) 2013-03-14 2017-09-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153214A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyl transferase inhibtors and uses thereof
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
WO2014152566A2 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
US9688714B2 (en) * 2013-07-03 2017-06-27 Epizyme, Inc. Substituted purine compounds
EP3027195B1 (en) 2013-07-29 2019-02-06 Dana-Farber Cancer Institute, Inc. Dot1l probes
EP3027774B1 (en) 2013-08-02 2020-07-15 Memorial Sloan-Kettering Cancer Center Methods for the detection and treatment of leukemias that are responsive to dot1l inhibition
US10143704B2 (en) * 2013-11-13 2018-12-04 Epizyme, Inc. Methods for treating cancer
EP3160477A4 (en) * 2014-06-25 2018-07-04 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US20170232030A1 (en) * 2014-08-13 2017-08-17 Epizyme, Inc. Combination therapy for treating cancer
US9458165B2 (en) 2014-08-27 2016-10-04 Dana-Farber Cancer Institute, Inc. DOT1L inhibitors
JP2017532312A (ja) * 2014-09-17 2017-11-02 エピザイム，インコーポレイティド 癌を治療するための併用療法
WO2016044649A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Injectable formulations for treating cancer
US10369166B2 (en) * 2014-09-30 2019-08-06 Susan Eve VECHT-LIFSHITZ Pharmaceutical compositions for treating ebola virus disease
WO2016123626A1 (en) * 2015-01-30 2016-08-04 Epizyme, Inc. Combination therapy for treating cancer
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP4643952A2 (en) 2016-01-26 2025-11-05 Memorial Sloan Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
SG10201913331VA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
AU2017233886B2 (en) * 2016-03-15 2022-10-20 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for the treatment of hematological malignancies
CN106432095B (zh) * 2016-09-09 2019-04-16 东南大学 匹莫苯丹关键中间体6-(3,4-二氨基苯基)-5-甲基-4,5-二氢哒嗪-3(2h)-酮的制备
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
CN109748943A (zh) * 2017-11-03 2019-05-14 中国科学院上海药物研究所 2’-c-甲基取代核苷类化合物及其制备与用途
CN109748944B (zh) * 2017-11-03 2021-12-10 中国科学院上海药物研究所 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途
US20200369667A1 (en) * 2017-12-05 2020-11-26 Angex Pharmaceutical, Inc. Heterocyclic compounds as prmt5 inhibitors
KR102118891B1 (ko) 2018-10-04 2020-06-04 성균관대학교산학협력단 매소니아노사이드 b를 유효성분으로 포함하는 혼합 직계성 백혈병 유전자 재배열 동반 백혈병 예방 및 치료용 약학적 조성물
AU2020205665C1 (en) * 2019-01-09 2025-10-02 Dana-Farber Cancer Institute, Inc. DOT1L degraders and uses thereof
JP2022523860A (ja) * 2019-03-11 2022-04-26 コラボレイティブ メディシナル デベロップメント， エルエルシー フェロトーシス関連障害の処置のための複素芳香族およびヘテロ二環式芳香族誘導体
CN110092804A (zh) * 2019-03-29 2019-08-06 广州盈升生物科技有限公司 一种含双环基团的嘌呤化合物及其制备方法
MX2021011606A (es) 2019-04-02 2021-12-10 Aligos Therapeutics Inc Compuestos dirigidos a prmt5.
CN113024620B (zh) * 2021-03-11 2023-02-28 沈阳药科大学 一种嘌呤衍生物及其制备方法和用途
WO2022271540A1 (en) * 2021-06-21 2022-12-29 Mayo Foundation For Medical Education And Research Inhibitors of dot1l
KR20240035820A (ko) 2021-07-09 2024-03-18 플렉시움 인코포레이티드 Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
AU2022316195A1 (en) * 2021-07-19 2024-01-04 Dana-Farber Cancer Institute, Inc. Targeting dot1l and smarca4/2 for the treatment of mllr leukemia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022572A1 (en) 2002-09-06 2004-03-18 Alchemia Limited Compounds that interact with kinases

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US20020127598A1 (en) 2000-03-27 2002-09-12 Wenqiang Zhou Solution-phase combinatorial library synthesis and pharmaceutically active compounds produced thereby
EP1138689A1 (en) 2000-03-28 2001-10-04 Roche Diagnostics GmbH N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization
EP1138688A1 (en) 2000-03-28 2001-10-04 Roche Diagnostics GmbH N8- and C8- linked purine bases as universal nucleosides used for oligonucleotide hybridization
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
JP2005533108A (ja) 2002-07-16 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのヌクレオシド誘導体
EP1572097A4 (en) 2002-09-30 2010-02-17 Smithkline Beecham Corp NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF INFECTIONS WITH THE HEPATITIS C-VIRUS
GB0301450D0 (en) * 2003-01-22 2003-02-19 Medical Res Council Protein crystal structure
CN100447149C (zh) * 2003-12-19 2008-12-31 弗·哈夫曼-拉罗切有限公司 Comt抑制剂
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7605143B2 (en) 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
US8058762B2 (en) * 2005-01-19 2011-11-15 Daikin Industries, Ltd. Rotor, axial gap type motor, method of driving motor, and compressor
WO2006078752A2 (en) 2005-01-21 2006-07-27 Methylgene, Inc. Inhibitors of dna methyltransferase
WO2006084281A1 (en) 2005-02-04 2006-08-10 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
US20060235037A1 (en) 2005-04-15 2006-10-19 Purandare Ashok V Heterocyclic inhibitors of protein arginine methyl transferases
US8461128B2 (en) 2005-04-15 2013-06-11 Sloan-Kettering Institute For Cancer Research Anti-microbial agents and uses thereof
JP5231251B2 (ja) 2006-02-02 2013-07-10 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素の阻害剤
WO2007100304A1 (en) 2006-03-02 2007-09-07 Agency For Science, Technology And Research Methods for cancer therapy and stem cell modulation
GB0607953D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US8188063B2 (en) 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
WO2008124150A1 (en) 2007-04-09 2008-10-16 University Of Virginia Patent Foundation Method of treating enteritis, intestinal damage, and diarrhea from c. difficile with an a2a adenosine receptor agonist
CN101417967A (zh) 2007-10-26 2009-04-29 浙江海正药业股份有限公司 组蛋白去乙酰酶抑制剂、其组合物及其应用
SI2207775T1 (sl) 2007-11-05 2012-05-31 Novartis Ag benzilamino karboksiacil piperidinski derivati kot inhibitorji CETP uporabni za zdravljenje bolezni kot je hiperlipidemija ali arterioskleroza
US20090181920A1 (en) 2008-01-09 2009-07-16 Pgxhealth, Llc Intrathecal treatment of neuropathic pain with a2ar agonists
AR072906A1 (es) 2008-08-06 2010-09-29 Novartis Ag Nucleosidos modificados utiles como antivirales
US20110171192A1 (en) 2008-09-05 2011-07-14 Hiroshi Tomiyama Substituted amine derivative and medicinal composition comprising same as the active ingredient
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
CN102066372B (zh) 2009-08-24 2014-09-17 苏州爱斯鹏药物研发有限责任公司 含脲基的5，6元杂芳双环化合物作为激酶抑制剂
SI2646444T1 (sl) * 2010-12-03 2016-09-30 Epizyme, Inc. Substituirane spojine purina in 7-deazapurina kot modulatorji epigenetskih encimov
EP2646441B1 (en) 2010-12-03 2015-12-02 Epizyme, Inc. Carbocycle-substituted purine and 7-deazapurine compounds
WO2012082436A2 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
KR20130124959A (ko) 2010-12-03 2013-11-15 에피자임, 인코포레이티드 히스톤 메틸전달효소의 7-데아자퓨린 조절제 및 그의 사용방법
EP2892536B1 (en) * 2012-09-06 2019-12-18 Epizyme, Inc. Method of treating leukemia
US9446064B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. Combination therapy for treating cancer
WO2014152566A2 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
EP3027774B1 (en) * 2013-08-02 2020-07-15 Memorial Sloan-Kettering Cancer Center Methods for the detection and treatment of leukemias that are responsive to dot1l inhibition
US10143704B2 (en) * 2013-11-13 2018-12-04 Epizyme, Inc. Methods for treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022572A1 (en) 2002-09-06 2004-03-18 Alchemia Limited Compounds that interact with kinases

Also Published As

Publication number Publication date
SI2646444T1 (sl) 2016-09-30
CA2819648C (en) 2018-05-01
MX2013006251A (es) 2013-10-01
RU2606514C2 (ru) 2017-01-10
HRP20160655T1 (hr) 2016-09-23
AU2011336415B2 (en) 2016-08-11
BR112013013659B8 (pt) 2024-02-27
CA2819648A1 (en) 2012-06-07
US20150366893A1 (en) 2015-12-24
JP2013544846A (ja) 2013-12-19
CN103391939B (zh) 2016-03-09
US9096634B2 (en) 2015-08-04
DK2646444T3 (da) 2016-06-27
AU2011336415A1 (en) 2013-06-20
US20180280422A1 (en) 2018-10-04
AR084408A1 (es) 2013-05-15
CN103391939A (zh) 2013-11-13
EP2646444A1 (en) 2013-10-09
US20210252035A1 (en) 2021-08-19
HK1189596A1 (zh) 2014-06-13
BR112013013659A2 (pt) 2016-09-06
IL226651A (en) 2016-11-30
KR20130125379A (ko) 2013-11-18
US8580762B2 (en) 2013-11-12
WO2012075381A1 (en) 2012-06-07
EP2646444B1 (en) 2016-03-16
TW201307348A (zh) 2013-02-16
BR112013013659B1 (pt) 2022-06-21
ES2577027T3 (es) 2016-07-12
RU2013130250A (ru) 2015-01-10
US20120142625A1 (en) 2012-06-07
JP5931905B2 (ja) 2016-06-08
US20140051654A1 (en) 2014-02-20
TWI537271B (zh) 2016-06-11

Similar Documents

Publication Publication Date Title
KR101923746B1 (ko) 후생적 효소의 조절자로서의 치환된 퓨린 및 7-데아자퓨린 화합물
ES2390921T3 (es) Inhibidores de la enzima activadora E1
EP2646441B1 (en) Carbocycle-substituted purine and 7-deazapurine compounds
US9029343B2 (en) Modulators of histone methyltransferase, and methods of use thereof
EP3122752B1 (en) 4'-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
Yoon et al. Design, synthesis and anticancer activity of fluorocyclopentenyl-purines and–pyrimidines
EP3580208B1 (en) 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol derivatives and related compounds as prs inhibitors for treating e.g. cancer
CA2853501A1 (en) Methyltransferase inhibitors for treating cancer
HK1189596B (en) Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes
Koszytkowska-Stawińska et al. Synthesis of aza-analogues of Ganciclovir
HK1227875B (en) 4'-substituted nucleoside-derivatives as hiv reverse transcriptase inhibitors
HK1124609B (en) Inhibitors of e1 activating enzyme

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20241124

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20241124

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20241124